Cover Image
市場調查報告書

全身發病型幼年類風濕性關節炎 (史迪爾氏症):開發中產品分析

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363107
出版日期 內容資訊 英文 141 Pages
訂單完成後即時交付
價格
Back to Top
全身發病型幼年類風濕性關節炎 (史迪爾氏症):開發中產品分析 Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 141 Pages
簡介

本報告提供全身發病型幼年類風濕性關節炎 (史迪爾氏症) 治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

全身發病型幼年類風濕性關節炎 (史迪爾氏症)的概要

治療藥的開發

  • 開發中產品的概要

全身發病型幼年類風濕性關節炎 (史迪爾氏症):企業開發中的治療藥

全身發病型幼年類風濕性關節炎 (史迪爾氏症):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

全身發病型幼年類風濕性關節炎 (史迪爾氏症):企業開發中的產品

全身發病型幼年類風濕性關節炎 (史迪爾氏症的)治療藥的開發企業

  • AbbVie Inc.
  • Alteogen Inc.
  • Biocon Limited
  • Coherus BioSciences, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Johnson & Johnson
  • Mabion SA
  • Marathon Pharmaceuticals, LLC
  • Momenta Pharmaceuticals, Inc.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Oncobiologics, Inc.
  • Oncodesign SA
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sandoz International GmbH
  • Swedish Orphan Biovitrum AB
  • Therapeutic Proteins International, LLC
  • UCB S.A.

全身發病型幼年類風濕性關節炎 (史迪爾氏症):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

全身發病型幼年類風濕性關節炎 (史迪爾氏症):暫停中的計劃

全身發病型幼年類風濕性關節炎 (史迪爾氏症):中止開發的產品

全身發病型幼年類風濕性關節炎 (史迪爾氏症):產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8173IDB

Summary

Global Markets Direct's, 'Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline Review, H1 2016', provides an overview of the Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)
  • The report reviews pipeline therapeutics for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) therapeutics and enlists all their major and minor projects
  • The report assesses Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Overview
  • Therapeutics Development
    • Pipeline Products for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Overview
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Therapeutics under Development by Companies
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Products under Development by Companies
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Alteogen Inc.
    • Biocon Limited
    • Coherus BioSciences, Inc.
    • Epirus Biopharmaceuticals, Inc.
    • Johnson & Johnson
    • Mabion SA
    • Marathon Pharmaceuticals, LLC
    • Momenta Pharmaceuticals, Inc.
    • Mycenax Biotech Inc.
    • Novartis AG
    • Oncobiologics, Inc.
    • Oncodesign SA
    • Panacea Biotec Limited
    • Pfizer Inc.
    • Sandoz International GmbH
    • Swedish Orphan Biovitrum AB
    • Therapeutic Proteins International, LLC
    • UCB S.A.
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abatacept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • abatacept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ABT-122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anakinra (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • canakinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • certolizumab pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • deflazacort - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • golimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • methotrexate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tofacitinib citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • upadacitinib tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Dormant Projects
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Discontinued Products
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Product Development Milestones
    • Featured News & Press Releases
      • May 27, 2016: Simponi Receives CHMP Positive Opinion For Treatment Of Polyarticular Juvenile Idiopathic Arthritis
      • Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)
      • Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)
      • Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis
      • Feb 12, 2015: ONS-3010 (Humira/Adalimumab Biosimilar) Meets Primary Endpoints In First Clinical Study
      • Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
      • Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris
      • May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis
      • Dec 19, 2012: Novartis's ACZ885 Significantly Relieves Symptoms In Patients With Serious Form Of Childhood Arthritis In Phase III Trials
      • Nov 08, 2012: Bristol-Myers Squibb To Present New Investigational Data On Orencia At 2012 American College Of Rheumatology Annual Scientific Meeting
      • Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012
      • Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis
      • Nov 07, 2011: Novartis's Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use In 45% Of Patients With Serious Form Of Childhood Arthritis
      • Sep 16, 2011: Novartis Study Says ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With Childhood Arthritis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by AbbVie Inc., H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Alteogen Inc., H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Biocon Limited, H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Johnson & Johnson, H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Mabion SA, H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Marathon Pharmaceuticals, LLC, H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Mycenax Biotech Inc., H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Novartis AG, H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Oncobiologics, Inc., H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Oncodesign SA, H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Panacea Biotec Limited, H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Pfizer Inc., H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Sandoz International GmbH, H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Swedish Orphan Biovitrum AB, H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Therapeutic Proteins International, LLC, H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by UCB S.A., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Dormant Projects, H1 2016
  • Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top